Clinical Trials Logo
  1. Home
  2. Recurrent Liver Carcinoma
  3. NCT03008343

Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer

Recurrent Liver Carcinoma Clinical Trial

Clinical Trial Summary

The aim of this study is the safety and efficacy of irreversible electroporation (IRE) plus natural killer (NK) immunotherapy to recurrent liver cancer.

Clinical Trial Description

By enrolling patients with recurrent liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using IRE and NK cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03008343
Study type Interventional
Source Fuda Cancer Hospital, Guangzhou
Contact
Status Completed
Phase Phase 1/Phase 2
Start date December 1, 2016
Completion date July 1, 2019
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02465060 - Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Phase 2